BIOMARKER:

TP53 mutation + Chr del(17p)

Entrez ID:

Related biomarkers:

‹

›

TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia CLL	TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia CLL	venetoclax + rituximab Sensitive: B - Late Trials	venetoclax + rituximab Sensitive: B - Late Trials
TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	LOXO-305 Sensitive: C3 – Early Trials	LOXO-305 Sensitive: C3 – Early Trials
TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia CLL	TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia CLL	LOXO-305 Sensitive: C3 – Early Trials	LOXO-305 Sensitive: C3 – Early Trials
TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	orelabrutinib Sensitive: C3 – Early Trials	orelabrutinib Sensitive: C3 – Early Trials
TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia CLL	TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia CLL	orelabrutinib Sensitive: C3 – Early Trials	orelabrutinib Sensitive: C3 – Early Trials
TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia CLL	TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia CLL	ibrutinib Sensitive: C3 – Early Trials	ibrutinib Sensitive: C3 – Early Trials
TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Acute Myelogenous Leukemia AML	TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Acute Myelogenous Leukemia AML	MGD006 Sensitive: C3 – Early Trials	MGD006 Sensitive: C3 – Early Trials
TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia CLL	TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia CLL	zanubrutinib Sensitive: C3 – Early Trials	zanubrutinib Sensitive: C3 – Early Trials